<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PIPECURONIUM BROMIDE</span><br/>(pi-pe-cu-ron'i-um)<br/><span class="topboxtradename">Arduan<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">nondepolarizing skeletal muscle relaxant</span><br/><b>Prototype: </b>Tubocurarine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Nondepolarizing neuromuscular blocking agent. Appears to lack vagolytic or autonomic activity and results in minimal cardiovascular
         effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Drug of choice in coronary artery bypass surgery and patients with coronary artery disease because it does not appear to cause
         tachycardia or elevated blood pressure as observed with other neuromuscular blocking agents.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to general anesthesia, and to provide skeletal muscle relaxation during surgery. Should only be used for procedures
         expected to last <img src="../images/special/greaterorequal.gif"/>90 min.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Skeletal muscle relaxation for endotracheal intubation.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pipecuronium or bromide.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with myasthenia gravis; renal failure; hepatic insufficiency; amyotrophic lateral sclerosis (ALS); burn patients;
         children and infants; pregnancy (category C), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunct for General Anesthesia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 85 to 100 mcg/kg, ideal body weight, given as rapid bolus over 510 sec or may give over 1 min if desired <span class="rdroute">IV Maintenance</span> Smaller supplemental doses (usually 525 mcg/kg) may be given to maintain muscle relaxation during long surgical procedures<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> Dose based on ideal body weight: <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute 10 mg vial with 10 mL of sterile water for injection, bacteriostatic water for injection (not for use in newborns),
                  D5W, NS, D5/NS, or RL. Do not dilute into or administer from large-volume IV solutions. Refrigerate when reconstituted and
                  use within 24 h.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 1015 sec.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, hypotension. <span class="typehead">Musculoskeletal:</span> Prolonged duration of action resulting in muscle weakness to paralysis resulting in respiratory insufficiency or apnea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Capreomycin</b> may increase the action of neuromuscular blocking agents. <b>Enflurane,</b>
<b>isoflurane</b> may prolong the pipecuronium-induced neuromuscular blockade. Dose reductions of pipecuronium may be needed. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 23 min. <span class="typehead">Peak:</span> 36 min. <span class="typehead">Duration:</span> Dose dependent: 5070 mcg/kg lasts approximately 1 h. Concomitant anesthetic agents will also affect duration of action. <span class="typehead">Distribution:</span> Approximately 32% protein bound (animal studies). <span class="typehead">Metabolism:</span> Partially metabolized in the liver. It is unknown if metabolites have any pharmacologic activity. <span class="typehead">Elimination:</span> Excreted by the kidneys. About 56% of the dose is excreted in the urine within 24 h. <span class="typehead">Half-Life:</span> 137161 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor hemodynamic status; clinically significant bradycardia, hypotension, and hypertension have occurred in a small percentage
            (
         </li><li>Use a peripheral nerve stimulator to monitor drug response.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>